Bacteraemia, antimicrobial susceptibility and treatment among Campylobacter-associated hospitalisations in the Australian Capital Territory: a review.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
    • Abstract:
      Background: Campylobacter spp. cause mostly self-limiting enterocolitis, although a significant proportion of cases require hospitalisation highlighting potential for severe disease. Among people admitted, blood culture specimens are frequently collected and antibiotic treatment is initiated. We sought to understand clinical and host factors associated with bacteraemia, antibiotic treatment and isolate non-susceptibility among Campylobacter-associated hospitalisations.
      Methods: Using linked hospital microbiology and administrative data we identified and reviewed Campylobacter-associated hospitalisations between 2004 and 2013. We calculated population-level incidence for Campylobacter bacteraemia and used logistic regression to examine factors associated with bacteraemia, antibiotic treatment and isolate non-susceptibility among Campylobacter-associated hospitalisations.
      Results: Among 685 Campylobacter-associated hospitalisations, we identified 25 admissions for bacteraemia, an estimated incidence of 0.71 cases per 100,000 population per year. Around half of hospitalisations (333/685) had blood culturing performed. Factors associated with bacteraemia included underlying liver disease (aOR 48.89, 95% CI 7.03-340.22, p < 0.001), Haematology unit admission (aOR 14.67, 95% CI 2.99-72.07, p = 0.001) and age 70-79 years (aOR 4.93, 95% CI 1.57-15.49). Approximately one-third (219/685) of admissions received antibiotics with treatment rates increasing significantly over time (p < 0.05). Factors associated with antibiotic treatment included Gastroenterology unit admission (aOR 3.75, 95% CI 1.95-7.20, p < 0.001), having blood cultures taken (aOR 2.76, 95% CI 1.79-4.26, p < 0.001) and age 40-49 years (aOR 2.34, 95% CI 1.14-4.79, p = 0.02). Non-susceptibility of isolates to standard antimicrobials increased significantly over time (p = 0.01) and was associated with overseas travel (aOR 11.80 95% CI 3.18-43.83, p < 0.001) and negatively associated with tachycardia (aOR 0.48, 95%CI 0.26-0.88, p = 0.02), suggesting a healthy traveller effect.
      Conclusions: Campylobacter infections result in considerable hospital burden. Among those admitted to hospital, an interplay of factors involving clinical presentation, presence of underlying comorbidities, complications and increasing age influence how a case is investigated and managed.
      (© 2021. The Author(s).)
    • References:
      J Glob Antimicrob Resist. 2019 Mar;16:76-80. (PMID: 30267925)
      Clin Infect Dis. 2001 Apr 15;32(8):1201-6. (PMID: 11283810)
      J Clin Pharmacol. 2016 Sep;56(9):1060-75. (PMID: 26865283)
      BMC Infect Dis. 2021 Jan 6;21(1):10. (PMID: 33407203)
      Clin Infect Dis. 2006 May 15;42(10):1368-74. (PMID: 16619147)
      J Med Microbiol. 2006 Jun;55(Pt 6):741-746. (PMID: 16687593)
      Clin Infect Dis. 2017 Nov 29;65(12):1963-1973. (PMID: 29194529)
      Medicine (Baltimore). 2010 Sep;89(5):319-330. (PMID: 20827109)
      J Hosp Med. 2016 May;11(5):336-40. (PMID: 26762577)
      QJM. 1996 Jul;89(7):515-22. (PMID: 8759492)
      Infect Dis (Lond). 2016 Nov-Dec;48(11-12):796-9. (PMID: 27320494)
      Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2101-2107. (PMID: 28623550)
      Clin Infect Dis. 1998 Feb;26(2):341-5. (PMID: 9502453)
      Clin Infect Dis. 2008 Sep 15;47(6):790-6. (PMID: 18699745)
      Epidemiol Infect. 2017 Mar;145(4):839-847. (PMID: 27938447)
      Am J Public Health. 2014 Jul;104(7):e108-14. (PMID: 24832415)
      Emerg Infect Dis. 2013 Jul;19(7):1155-6. (PMID: 23763834)
      Lancet. 2010 Dec 11;376(9757):1987. (PMID: 21146103)
      Eur J Microbiol Immunol (Bp). 2012 Mar;2(1):76-87. (PMID: 24611124)
      Microb Genom. 2018 Jan;4(8):. (PMID: 30024366)
      J Chronic Dis. 1987;40(5):373-83. (PMID: 3558716)
      BMC Infect Dis. 2005 Sep 14;5:70. (PMID: 16162289)
      Clin Infect Dis. 2006 Feb 15;42(4):498-506. (PMID: 16421794)
      BMC Public Health. 2011 Jan 12;11:32. (PMID: 21226938)
      EFSA J. 2017 Feb 23;15(2):e04694. (PMID: 32625402)
      Clin Microbiol Infect. 2010 Jan;16(1):57-61. (PMID: 19673969)
      Clin Infect Dis. 2017 Oct 30;65(10):1624-1631. (PMID: 29020144)
      Clin Microbiol Infect. 2015 Apr;21(4):295-301. (PMID: 25677625)
      Scand J Infect Dis. 1995;27(2):145-8. (PMID: 7660078)
      Clin Infect Dis. 2011 Oct;53(8):e99-e106. (PMID: 21921217)
      Clin Infect Dis. 1997 Dec;25(6):1414-20. (PMID: 9431389)
      Appl Environ Microbiol. 2017 May 31;83(12):. (PMID: 28411226)
      Emerg Infect Dis. 2012 Sep;18(9):1453-60. (PMID: 22932272)
      Med J Aust. 2016 Nov 21;205(10):S16-S20. (PMID: 27852197)
      Arch Intern Med. 2008 Nov 24;168(21):2333-9. (PMID: 19029498)
      J Emerg Med. 2008 Oct;35(3):255-64. (PMID: 18486413)
      Infect Dis Clin North Am. 2007 Sep;21(3):659-72, viii. (PMID: 17826617)
      JAMA. 2012 Aug 1;308(5):502-11. (PMID: 22851117)
      Clin Microbiol Infect. 2015 Aug;21(8):744-9. (PMID: 25769427)
      Emerg Infect Dis. 2013 Oct;19(10):1653-5. (PMID: 24047729)
      Int J Antimicrob Agents. 2007 Sep;30(3):195-201. (PMID: 17420115)
      Clin Microbiol Infect. 2016 Apr;22(4):391-393. (PMID: 26685775)
      Clin Microbiol Rev. 2015 Jul;28(3):687-720. (PMID: 26062576)
    • Grant Information:
      APP107490 National Health and Medical Research Council; APP1145997 National Health and Medical Research Council
    • Contributed Indexing:
      Keywords: Antimicrobial susceptibility; Antimicrobial therapy; Bacteraemia; Campylobacter infections; Comorbidity; Elderly; Hospitalisation; Incidence
    • Accession Number:
      0 (Anti-Bacterial Agents)
      0 (Anti-Infective Agents)
    • Publication Date:
      Date Created: 20210822 Date Completed: 20210924 Latest Revision: 20210924
    • Publication Date:
      20240104
    • Accession Number:
      PMC8379883
    • Accession Number:
      10.1186/s12879-021-06558-x
    • Accession Number:
      34419003